Drugs / Donor NK Cells
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06641648 | Dec 2024 → Dec 2025 overdue | acute myeloid leukemia | Peking University First Hospital | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03050216 | May 2017 → Dec 2019 | acute myeloid leukemia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT02100891 | Mar 2013 → Jun 2020 | Ewing sarcoma, central nervous system neoplasm, neuroblastoma, osteosarcoma +1 | Monica Thakar | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donor NK cells | “Donor NK cells injection is a non-genetically modified natural killer cells therapy derived from a healthy donor.” NCT06641648 ↗2“followed by donor NK cells on day +7 after transplant” NCT02100891 ↗ “ALT-803 Stimulated Donor NK Cells” NCT03050216 ↗ |
| Modality | Cell therapy | “cellular and adoptive immunotherapy study using human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (HCT) followed by an early, post-transplant...” NCT02100891 ↗ |